Insulin signaling and oxidative stress: Bridging the gap between type 2 diabetes mellitus and Alzheimer's disease

Abstract

Background

Type 2 diabetes mellitus (T2D) and Alzheimer's disease (AD) are two prevalent chronic diseases that pose significant global health challenges. Increasing evidence suggests a complex bidirectional relationship between these conditions, where T2D elevates the risk of AD, and AD exacerbates glucose metabolism abnormalities in T2D.

Objective

This review explores the molecular mechanisms linking T2D and AD, focusing on the role of insulin signaling pathways and oxidative stress.

Methods

A comprehensive literature search from PubMed, Web of Science, and other relevant databases was conducted and analyzed.

Results

Insulin resistance in T2D leads to impaired insulin signaling in the brain, contributing to cognitive decline and the development of AD. Hyperglycemia-induced oxidative stress exacerbates neuronal damage, promoting the formation of amyloid-β plaques and neurofibrillary tangles characteristic of AD. Clinically antidiabetic drugs such as metformin show potential against AD in preclinical studies; Many natural products such as Dendrobium nobile Lindl. have anti-T2D efficacy and are also effective against AD in various in vivo and in vitro models.

Conclusions

Improving insulin resistance and reducing oxidative stress are important strategies in the treatment of T2D and AD. To understand the bridging role of insulin singling and oxidative stress in T2D and AD will provide insights and broader applications in alleviating T2D and AD.

Keywords

Alzheimer's disease insulin signaling oxidative stress type 2 diabetes mellitus

Introduction

Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by elevated blood sugar levels and insulin-related issues, such as insulin resistance and a relative lack of insulin.¹ T2D has increased prevalence among the elderly.² This condition poses a significant global health threat, as the prevalence of impaired glucose tolerance (IGT) and diabetes has quadrupled over the past three decades.³ Currently, T2D affects over 463 million people worldwide, a number projected to rise to 700 million by 2045.⁴ T2D accounts for more than 90% of all diabetes cases.⁵

Figure 1.

Impact and potential mechanisms of insulin signals and oxidative stress on AD and T2D.

Alzheimer's disease (AD) is the most common age-related neurodegenerative illness, affecting approximately two-thirds of the over 50 million dementia sufferers worldwide.⁶ Clinically, AD is marked by progressive memory loss, behavioral and personality changes, and a continual decline in cognitive abilities. Its primary pathological features include the accumulation of amyloid-β (Aβ) peptides, tau protein deposition, and significant neuronal loss in the brain.⁷ Despite over a century of research, effective disease-modifying therapies remain elusive, largely due to the complex and multifactorial nature of the disease.

T2D and AD are interconnected, with individuals having diabetes more likely to develop AD.⁸ T2D induces neurodegeneration through abnormal glucose metabolism and impaired insulin signaling, affecting normal cellular processes, cerebral blood flow, and neuronal structure, leading to hyperphosphorylation of tau protein and the formation of neurofibrillary tangles (NFTs).^9,10 Concurrently, diabetes promotes the accumulation of Aβ peptides and the formation of Aβ plaques, further contributing to neurodegeneration and increasing the risk of AD.¹¹ Due to the association between disrupted glucose metabolism, insulin dysfunction and AD, some researchers refer AD as “type 3 diabetes”.¹²

Oxidative stress is a key factor in the development of both T2D and AD.^13,14 Excessive production of reactive oxygen species (ROS) damages mitochondrial function, alters cellular metabolism, and weakens antioxidant defenses, all of which negatively impact cognition function.¹⁵ These changes can also directly affect neurotransmission and synaptic plasticity in the brain. In diabetes, oxidative stress contributes to cellular damage even before many diabetic complications arise.¹⁶ Elevated glucose levels lead to increased ROS production, which reduces insulin sensitivity and induces the apoptosis of insulin-producing pancreatic cells, thereby exacerbating the progression of diabetes mellitus.¹⁷

There are several hypotheses to link T2D and AD, for example, In T2D, AMPK can regulate glucose transporter-4 to improve insulin resistance. In AD, AMPK can improve abnormal brain energy metabolism by reducing Aβ deposition and tau hyperphosphorylation.¹⁸ GSK-3β is a common kinase in insulin signaling transduction and tau protein phosphorylation in T2D and in AD.¹⁹ Chronic TLR4 activation may contribute to insulin resistance in T2D, but also contribute to Aβ deposition and oxidative stress in AD.²⁰ Therefore, insulin signaling and oxidative stress are two major factors connecting T2D with AD. The aim of this review is to discuss the bridging roles of oxidative stress and insulin signaling in the disease process of T2D combined with AD and related therapeutic strategies (Figure 1).

Insulin signaling in type 2 diabetes and Alzheimer's disease

Insulin signaling and T2D

T2D is known as non-insulin-dependent diabetes and is impacted by a number of hereditary and environmental variables. It is also associated with obesity and islet beta cell degeneration.^21,22 Insulin resistance represents a hallmark in the pathogenesis of T2D. At physiological state, insulin binds to the insulin receptor, leading to the phosphorylation of insulin receptor substrate 1 (IRS1). This activation causes PI3 kinases (PI3 e) to phosphorylate PIP2, triggering the Akt pathway. GLUT4 is consequently translocated to the plasma membrane in insulin-sensitive tissues such as skeletal muscle and adipocytes. This translocation lowers blood glucose levels by promoting glucose uptake in the cells.^23,24 Additionally, elevated insulin levels alter PI3 K function, leading to the phosphorylation of Rac instead of PIP2, activating NADPH oxidase 4, and generating substantial amounts of ROS.²⁵ Research indicates that prolonged exposure to glucose adversely affects insulin gene expression in beta cell lines. Experiments conducted with the HIT-T15 beta cell line demonstrated that extended exposure to high doses of glucose resulted in decreased levels of insulin mRNA, reduced insulin content, and impaired glucose-induced insulin release.²⁶ Thus, regulating insulin signaling, reducing insulin resistance, and lowering blood sugar may help treat T2D, and is a key target for improving T2D related complications.

Insulin signaling and AD

Insulin is a peptide hormone that is primarily secreted by pancreatic β-cells, which is known to influence glucose metabolism, maintain brain function, promote neuronal growth, neurite growth and repair.^27,28 Insulin signaling pathway involves binding to insulin and insulin-like growth factor receptors, activating PI3 K, and subsequently promoting Akt phosphorylation, which ensures glucose homeostasis.^29,30 Insulin resistance (IR) was originally defined as the need for substantial insulin amounts in T2D patients. Currently, it refers to reduced responsiveness to insulin's metabolic actions, such as impaired gluconeogenesis in the liver and decreased glucose uptake in muscle and adipose tissue.³¹ Clinically, IR is characterized by insulin-target cells being less sensitive to elevated insulin levels.³² It underlies many modern disorders, including metabolic syndrome, such as T2D and AD.³³

It is worthy of note that insulin is an essential element of the nervous system and affects the number of neurological illnesses that arise from insulin abnormality, it regulates behavioral and cognitive processes as well as central nervous system functions.^34,35 Under normal physiological conditions, insulin readily traverses the blood-brain barrier (BBB) via receptor-mediated transport mechanisms. However, conditions like inflammation and obesity can modulate this process.³⁶ In addition, insulin can reach parts of the brain, like the hypothalamus, that are not protected by the BBB.³⁷ With aging, there is a noted decline in insulin transport into the cerebrospinal fluid (CSF).^38,39 This decline may contribute to compromised brain insulin action, predisposing individuals to age-related cognitive dysfunction and neurodegenerative diseases. This assertion is substantiated by findings of decreased CSF insulin levels observed in individuals with AD in several studies.⁴⁰

Furthermore, in elderly individuals without dementia, a reduction in cortical insulin levels and receptor binding correlates with advancing age.⁴¹ In AD, disruptions in insulin signaling are apparent in brain tissue. These alterations involve the reduced mRNA and protein expression of insulin, insulin receptor, and IRS1.²⁸ Moreover, a positive association between AD severity and elevated phosphorylation levels of IRS1 and other insulin signaling pathways is found.⁴² In addition, people with AD exhibit decreased sensitivity to peripheral insulin and hyperinsulinemia during fasting and in reaction to an oral glucose tolerance test.⁴³ Compared to controls, AD patients have fewer or mis-localized insulin receptors—that is, receptors that are not on the membrane surface—and a lower receptor affinity for insulin in their brains.⁴⁴ In animal models of AD, both transgenic and non-transgenic mice frequently show compromised insulin signaling. Specifically, insulin resistance signals have been observed in the hypothalamus of APP/PS1 mice.⁴⁵ Moreover, central administration of amyloid-β oligomers (AβOs) could induce peripheral insulin resistance, similarly affecting models like APP/PS1 and 3xTg-AD mice.⁴⁶

It is reported that the main component of amyloid plaques in the brains of AD patients is Aβ, a peptide derived from amyloid-β protein precursor (AβPP), which AβPP is cleaved by the enzyme α-secretase within its extracellular domain. Proteolysis of AβPP by beta-site amyloid precursor protein-cleaving enzyme 1 (BACE-1), β-secretase, and γ-secretase results in the production of Aβ, a neurotoxic peptide. Disruptions in the production, clearance, and aggregation of Aβ lead to its accumulation, which may be a primary etiological factor in AD.^47,48 Insulin is reported to influence AβPP metabolism, thereby altering the balance between Aβ synthesis and degradation, while reduced insulin levels are linked to increased Aβ production and amyloid plaque formation in the brain.⁴⁹ Additionally, insulin has been demonstrated to reduce extracellular levels of Aβ_1–40 and Aβ_1–42 in primary cultures of rat cortical neurons and neuroblastoma SH-SY5Y cells.⁵⁰ In addition, small oligomers of Aβ are involved in downstream events, including synaptotoxicity, that trigger neurodegenerative processes in AD. it has been discovered that Aβ oligomers may suppress of IRS-1 in both in vivo and in vitro models.^51,52 In additional research on the impact of Aβ oligomers in animals, the Aβ₄₂ peptide was discovered to cause APP/PS1E9 mice to develop hepatic insulin resistance by activating Janus Kinase 2 (JAK2).

Moreover, a mild elevation in insulin levels will lead to an increase in insulin-degrading enzyme (IDE) activity.⁵³ Under normal conditions, Aβ can be broken down by IDE; therefore, if IDE activity is high enough (not IDE levels), it will help remove Aβ from the brain. However, during insulin resistance, insulin levels rise significantly and affect other pathological processes. Under this condition, IDE primarily functions to degrade insulin, which in turn reduces the clearance of Aβ, ultimately leading to Aβ accumulation.^54,55

Tau is a protein predominantly located in neuronal axons, where it plays a crucial role in stabilizing microtubules. In AD, one of the primary pathological characteristics is the excessive phosphorylation of tau protein, which leads to the formation of NFTs. These NFTs are believed to impair neuronal function and contribute to the progressive degeneration of neurons. Additionally, smaller aggregates of hyperphosphorylated tau are implicated in further disrupting cellular processes and exacerbating neurodegeneration in AD.^56,57 Tau hyperphosphorylation is increased in an insulin-deficient AD mice model.⁵⁸ Impaired insulin signaling leads to decreased activity of the PI3K-Akt pathways and activation of GSK-3β, which in turn promotes tau phosphorylation.⁵⁹ Insulin inhibits GSK-3β, which prevents tau from being phosphorylated. While insulin resistance is present, GSK-3β activity is elevated, leading to tau phosphorylation and the formation of NFTs.⁶⁰ Additionally, peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Studies have demonstrated a significant increase in tau phosphorylation upon deletion of the IGF-1 and IRS-2 genes. And tau phosphorylation is specially enhanced at two distinct GSK-3β targeted sites following deletion of the IGF-1 gene.^61,62 According to an analysis, people with T2D had higher CSF tau concentrations than normal people.⁶³ Increased peripheral insulin resistance has been associated with lower cognitive scores and higher levels of both phosphorylated and total tau protein in patients. Studies using tau knockout mice have demonstrated that reduced brain insulin sensitivity is associated with abnormal synaptic plasticity and deficits in short-term memory.⁶⁴

Interaction of insulin signaling in T2D and AD

Impaired insulin signaling in T2D leads to hyperglycemia and hyperinsulinemia, which may affect brain insulin levels and function through the blood-brain barrier. Disrupted brain insulin signaling in AD reduces the expression and functionality of insulin receptors and IRS1. These disruptions in insulin signaling may promote the production and deposition of Aβ and pathological changes in tau protein, exacerbating neuroinflammation and neuronal death. Earlier research revealed that reduced brain insulin receptors (IR) sensitivity, hypo-phosphorylation of the IR, and reduced downstream signaling including IRS1 are all observed in AD patients.⁶⁵ Impaired insulin signaling leads to defective glucose uptake and utilization, resulting in decreased energy production, a phenomenon consistent with that observed in the diabetic Zucker rat model.^65–67 This energy deficit is accompanied by increased levels of ROS and reactive nitrogen species, which not only cause oxidative and nitrosative damage to mitochondria but also disrupt the pathways involved in synaptic plasticity, leading to neuronal loss, cognitive decline, and cerebral degeneration.^68–70 Furthermore, this imbalance results in an excess of ROS within mitochondria, promoting the accumulation of Aβ peptides and causing oxidative damage to proteins, lipids, and nucleic acids in the brain, ultimately resulting in neuronal death.^71,72

Oxidative stress in type 2 diabetes and Alzheimer's disease

Oxidative stress and T2D

Pancreatic beta-cells, similar to neurons, exhibit limited expression of antioxidant enzymes, rendering them more vulnerable to oxidative stress.⁷³ ROS modify various signaling pathways within cells, playing a significant role in influencing glucose tolerance and insulin sensitivity.⁷⁴ The generation of ROS activates stress-sensitive pathways, including NF-κB, JNK/SAPK, and p38 MAPK, leading to cellular damage and complications in T2D.^26,75 Studies examining islets isolated from the pancreases of individuals with T2D have revealed increased markers of oxidative stress, including the lipid peroxidation products malondialdehyde and 4-hydroxynonenal,^76,77 and these markers are closely associated with the degree of impairment in glucose-stimulated insulin secretion.

Additionally, prolonged exposure to fatty acids in pancreatic beta cells has been shown to suppress insulin gene expression.^78,79 A cross-sectional study involving elderly individuals with impaired fasting glucose or T2D revealed a negative association between serum 25-hydroxyvitamin D levels and circulating oxidative stress biomarkers.^80,81 These biomarkers included advanced glycation end products, advanced oxidation protein products, susceptibility of low-density lipoprotein to oxidation, and nitric oxide metabolites.⁸² Moreover, multiple studies indicate that lipotoxicity induces oxidative stress in beta-cells, thereby compromising their function and viability,^83,84 and contributing to the initiation and progression of T2D. It can be seen that while ROS is a cellular signal that is necessary for certain physiological processes, its accumulation caused by oxidative stress, high blood glucose and progressive insulin resistance interact, exacerbate the process of T2D disease. Therefore, blocking the vicious cycle of oxidative stress-T2D circles is important in the treatment of disease.

Oxidative stress and AD

Oxidative stress occurs when there is an imbalance between harmful free radicals and the body's antioxidant defenses, leading to an excess of free radicals that can damage lipids, proteins, and nucleic acids.⁸⁵ The extent and nature of the damage caused by free radicals can vary depending on their site of generation, the specific type of free radicals involved and their half-lives, their ability to move to different parts of the body from their point of origin.⁸⁶

There are two categories of ROS: radicals and non-radicals. Radicals include superoxide (O₂•⁻), alkoxyl (RO•), peroxyl (ROO•), hydroxyl (OH•), hydroperoxyl (HO₂•), and nitric oxide (NO•). Non-radicals consist of ozone (O₃), singlet oxygen (¹O₂), hypochlorous acid (HOCl), hydrogen peroxide (H₂O₂), organic peroxides (ROOH), and aldehydes (RCHO).⁸⁷ There is mounting evidence that oxidative stress plays a critical role in the development of various human diseases, including both types of diabetes, the progression of neurodegenerative disorders, and cardiovascular disease.^85,86

The brain is susceptible to the harmful effects of oxidative stress due to its structure, rapid metabolism, and high lipid levels.⁸⁸ Subjects with mild cognitive impairment exhibit significantly higher levels of oxidative changes in the biological macromolecules of hippocampal tissue.⁸⁹ The studies suggest that in elderly individuals who are cognitively intact but exhibit AD pathology, oxidative stress is elevated and synaptic protein levels are lowered.⁹⁰ This indicates that oxidative damage is already present in the initial preclinical phase of AD. Furthermore, oxidative stress markers such as F2-isoprostanes, malondialdehyde, and trans-4-hydroxy-2-nonenal are found to be upregulated in brain samples and various biological fluids (CSF, plasma, and urine samples) collected from patients with AD and moderate cognitive impairment.^91,92 Oxidative stress has also been demonstrated to worsen the accumulation of Aβ and the deposition of NFTs in AD patients, and in models with PS1/PS2 and AβPP defects, as well as in transgenic Tg2576 mouse brains.⁹³ Pre-clinical research has shown an increase in oxidative stress in the brain's cortex and hippocampus tissues as AD progresses. In the case of model AD rats, the introduction of Aβ₄₂ peptide into the forebrain can result in oxidative stress in the hippocampal tissue,⁹⁴ while oxidizing agents can raise local Aβ₄₂ levels in the interstitial fluid in the hippocampal tissue of the mice.⁹⁵ On the one hand neurons exposed to Aβ_1–42 demonstrated heightened vulnerability to oxidative stress, potentially due to elevated levels of the pro-apoptotic protein Bcl-2-Associated X-protein and downregulation of the anti-apoptotic Bcl-2 protein.⁹³ On the other hand, excessive ROS might affect the production of Aβ by increasing the amount of amyloid precursor protein and changing the activity of important enzymes like β-secretase and γ-secretase, which are involved in digesting Aβ. Furthermore, oxidative stress stimulates autophagy, which in turn causes Aβ to accumulate in lysosomes and lysosomal enzymes released in turn cause neuronal death.⁹⁶

Under high levels of oxidative stress, p38 MAPK activation increases β-secretase production and Aβ deposition, while GSK-3β activation leads to tau phosphorylation and NFT formation.⁹⁷ In addition, tau-containing NFTs and elevated levels of heme oxygenase-1 (HO-1) colocalize in the brains of AD patients. Significant HO-1 activity is observed in the hippocampus, cortex, and subcortical white matter. In AD, senile plaques and NFTs also show HO-1 immunoreactivity.^98,99 HO-1 degrades the prooxidant heme into biliverdin, which is then reduced to bilirubin, releasing ferrous iron and carbon monoxide in the process. This reduction in oxidative stress is attributed to bilirubin's ability to scavenge radicals, while carbon monoxide offers neuroprotection through its anti-apoptotic and anti-inflammatory properties.¹⁰⁰ Research involving Cu/Zn superoxide dismutase (SOD) deficient animals revealed that increased oxidative stress, particularly in hippocampal tissue, results in cognitive decline similar to that seen in elderly mice.^101,102 Furthermore, studies have indicated that both AD patients and animal models exhibit decreased levels of antioxidant enzymes.¹⁰³

Preclinical research has demonstrated that the progression of AD in mouse and rat models can be slowed down by correcting mitochondrial dysfunction through the targeted delivery of antioxidants.¹⁰⁴ Vitamin E, a lipophilic antioxidant found in membranes, has been associated with memory loss in aging and dementia. Supplementing with vitamin E increases its levels in AD and decreases the susceptibility of lipoproteins to oxidation.¹⁰⁵ Additionally, vitamin E has been shown to reduce Aβ and tau levels in Tg2576 mice.¹⁰⁶ In general, improving the body's antioxidant system's defense capabilities and improving oxidation restoration balance, can significantly improve the disease process of AD and is an indispensable part of AD treatment.

Interaction of oxidative stress in T2D and AD

Studies suggest that increased diabetic mortalities can be attributed to the rise in vascular diseases, potentially due to oxidative damage.^107,108 Likewise, in diabetic rats and the streptozotocin (STZ) model of T2D, the prefrontal cortex, amygdala, and hippocampal regions exhibit decreased activity of antioxidant enzymes such as catalase and SOD, along with a simultaneous increase in lipid peroxidation products.^100,109 An overproduction of ROS creates an oxidative stress environment, destabilizing redox signaling.⁷⁵ Impaired redox signaling promotes pro-inflammatory and pro-fibrotic pathways, which negatively impact insulin metabolic signaling. Excessive ROS production inhibits the expression of MaFA (mature, adult β-cells express transcription factors), a critical component of the insulin secretion pathway, and the transcription of the insulin gene is controlled by the basic leucine zipper transcription factor family.¹¹⁰ Adult mice deficient in MafA displayed reduced expression of insulin secretion genes, fasting hyperglycemia, and impaired glucose-stimulated insulin secretion.¹¹¹ Inhibition of p38 MAPK-mediated MaFA degradation can enhance insulin production in db/db mice.¹¹² Oxidative stress can activate p38 MAPK, leading to MaFA degradation and affecting β-cell function and insulin production.¹¹³ Another aspect is chronic oxidative stress-induced inflammation can damage β-cells and induce apoptosis by activating the NF-κB signaling, which promotes the expression of pro-apoptotic Bcl-2 family members.^114,115 Moreover, the brain, known for its high cholesterol content, also experiences elevated levels of oxysterols such as 27-OHC, 7β-OHC, and 7-KC-in AD murine brains,¹¹⁶ which further exacerbate cellular damage by sustaining free-radical chain reactions and worsening insulin resistance.

Additionally, a study revealed that Nrf2 depletion in mice on a high-fat diet can induce hepatic insulin resistance by activating the NF-κB signaling pathway.^117,118 Nrf2-KO animals exhibited lower glutathione levels and higher malondialdehyde levels, indicating increased oxidative stress in T2D and AD.^119,120 The results suggest that targeting oxidative stress and insulin resistance may enhance antioxidant benefits and thereby improve both T2D and AD.

New therapeutic strategies for type 2 diabetes and AD

Drugs for T2D may have potential against AD

Due to the overlap in the pathological processes of T2D and AD, medications developed for T2D are being investigated for their potential to conquer AD. Among these medications are metformin (MET), glucagon-like peptide-1 receptor agonists, peroxisome proliferator-activated receptor gamma agonists, DDP-4 inhibitors and SGLT2 inhibitors.¹²¹ Research on these treatments demonstrates the promising avenues for combating AD in preclinical settings.

For example, MET is a widely used oral anti-diabetic medication that lowers blood glucose levels through various mechanisms. Studies in STZ-induced Swiss mice and APP/PS1 mice indicate that MET may have therapeutic potential for AD.¹²¹ Additionally, MET was found to markedly decrease BACE1 protein expression and activity in cell culture models, thereby reducing BACE1 cleavage products and the production of Aβ.¹²² the pancreatic peptide amylin analogue pramlintide reduces amyloid accumulation in the brain and improves memory and learning in AD model mice.¹²³ Similarly, in the senescence-accelerated mouse model (SAMP8), which exhibits pathophysiological features similar to those of AD, MET is effective against AD symptoms. Pramlintide (an amylin analog used for the management of T2D) has been shown to promote synaptogenesis by reducing inflammation and oxidative stress and improve AD pathology and cognitive impairment.¹²⁴ However, despite its promising results in many preclinical studies, the outcomes in clinical trials still need further investigation.¹²¹

Natural products in T2D and AD treatment

Natural products are a valuable source of lead compounds for T2D and AD treatment due to their unique structures, multi-target capabilities, and diverse activities.¹² These natural products include flavonoids (quercetin), polyphenols (resveratrol), polysaccharides (from Dendrobium nobile Lindl.), alkaloids (berberine), etc.^12,125,126

Take Dendrobium nobile Lindl. alkaloids (DNLA) as an example, in animal models of T2D, such as in KK-Ay mice, DNLA lower blood sugar levels, enhance IR, improving insulin signaling, and protect the pancreatic β cells of the pancreatic islets.¹²⁷ In db/db mice model, the pancreas of db/db mice exhibits shorter telomeres, and DNLA has been shown to delay this shortening while increasing telomerase activity.¹²⁸ In high-fat diet-induced diabetic rat models, DNLA alleviates pancreatic damage.¹²⁹ It should be noted that in Aβ_25–35-induced AD rat models, DNLA exerts neuroprotective effects by preventing neuronal and synaptic loss while improving cognitive dysfunction through the upregulation of synapses and postsynaptic density protein 95.^130,131 In the brain of rats, DNLA can also lessen neuronal death and ameliorate the neuronal disturbance produced by LPS, oxygen-glucose deprivation and reperfusion.¹² DNLA is also effective in high methionine-diet causes AD-like symptoms mouse model,¹³² in the accelerated aging SAMP8 mouse model^133,134 and in APP/PS1 model mice,¹³⁵ DNLA demonstrates anti-aging effects by inhibiting cellular aging processes and decreasing neuronal degeneration, increasing Aβ clearance and alleviating neuronal damage. In in vitro experiment, DNLA not only activates autophagy through the mTOR/ULK1 signaling pathway,¹³⁶ but also reduces the level of cellular oxidative stress and thus inhibits the mitochondrial-mediated apoptosis pathway to protect PC12 cell from Aβ_25–35 cytotoxicity.¹³⁷ Thus, DNLA is effective against both T2D and AD by reducing oxidative damage and improving insulin signaling pathways, thereby mitigating the harmful effects of both T2D and AD. Due to their dual action on these pathological mechanisms, DNLA holds promise as a natural therapeutic option for managing and potentially preventing the progression of T2D and AD.

Conclusions and perspectives

Insulin resistance (IR) and oxidative stress are key factors that link the pathologies of T2D and AD. IR is commonly associated with T2D, leads to impaired glucose metabolism and increased oxidative stress, which in turn damages neurons and contributes to the development of AD features, such as Aβ plaques and tau protein tangles. In the brain, IR disrupts signaling pathways essential for cognitive function, further accelerating neurodegeneration. Oxidative stress exacerbates these effects by promoting inflammation and neuronal damage. The bidirectional relationship between T2D and AD suggests that improving insulin signaling and targeting oxidative stress could offer promising therapeutic strategies for managing both conditions.

Current clinical treatments for T2D and AD can only alleviate symptoms to a limited extent, and halting the disease's progression remains challenging. By conducting a more in-depth investigation into the relationship between T2D and AD, therapeutic strategies for them could focus on addressing the shared pathological mechanisms, particularly focusing on the interactions between IR and oxidative stress. To understand the bridging role of insulin singling in T2D and AD will provide insights and broader applications in alleviating T2D and AD.

Footnotes

Acknowledgments

Thanks for the support of Guizhou Provincial Major Project (No: [2015] 5010).

ORCID iD

Jingshan Shi

Author contributions

Fengqing Xu (Investigation; Methodology; Validation; Visualization; Writing – original draft; Writing – review & editing); Jingshan Shi (Conceptualization; Funding acquisition; Supervision; Writing – review & editing).

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data availability

The data that support the findings of this study are available from the corresponding author, [J.S S], upon reasonable request.

References

Pollakova

Andreadi

Pacifici

, et al. The impact of vegan diet in the prevention and treatment of type 2 diabetes: a systematic review. Nutrients 2021; 13: 2123.

Oliveira

Tostes

Queiroz

, et al. Insulin mediated improvement in glycemic control in elderly with type 2 diabetes mellitus can improve depressive symptoms and does not seem to impair health-related quality of life. Diabetol Metab Syndr 2015; 7: 55.

Retnakaran

Hanley

, et al. Subtypes of gestational diabetes and future risk of pre-diabetes or diabetes. EClinicalMedicine 2021; 40: 101087.

Zhu

, et al. FX5, A non-steroidal glucocorticoid receptor antagonist, ameliorates diabetic cognitive impairment in mice. Acta Pharmacol Sin 2022; 43: 2495–2510.

Fang

Wang

Coresh

, et al. Trends in diabetes treatment and control in U.S. adults, 1999–2018. N Engl J Med 2021; 384: 2219–2228.

Guzman-Martinez

Calfío

Farias

, et al. New frontiers in the prevention, diagnosis, and treatment of Alzheimer's disease. J Alzheimers Dis 2021; 82: S51–S63.

Iso-Markku

Kujala

Knittle

, et al. Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies. Br J Sports Med 2022; 56: 701–709.

Piatkowska-Chmiel

Herbet

Gawronska-Grzywacz

, et al. The role of molecular and inflammatory indicators in the assessment of cognitive dysfunction in a mouse model of diabetes. Int J Mol Sci 2021; 22: 3878.

Shi

Fang

, et al. Quercetin ameliorates diabetic encephalopathy through SIRT1/ER stress pathway in db/db mice. Aging 2020; 12: 7015–7029.

10.

Park

Jung

Kim

, et al. Repeated hypoxia exposure induces cognitive dysfunction, brain inflammation, and amyloidβ/p-Tau accumulation through reduced brain O-GlcNAcylation in zebrafish. J Cereb Blood Flow Metab 2021; 41: 3111–3126.

11.

Honarnejad

Daschner

Gehring

, et al. Identification of tetrahydrocarbazoles as novel multifactorial drug candidates for treatment of Alzheimer's disease. Transl Psychiatry 2014; 4: e489.

12.

Huang

Mao

, et al. Natural bioactive compounds in Alzheimer's disease: from the perspective of type 3 diabetes mellitus. Front Aging Neurosci 2023; 15: 1130253.

13.

Tang

. The cellular and molecular processes associated with scopolamine-induced memory deficit: a model of Alzheimer's biomarkers. Life Sci 2019; 233: 116695.

14.

Scholtens

Bain

Reisetter

, et al. Metabolic networks and metabolites underlie associations between maternal glucose during pregnancy and newborn size at birth. Diabetes 2016; 65: 2039–2050.

15.

Gurunathan

Jeyaraj

Kang

, et al. Melatonin enhances palladium-nanoparticle-induced cytotoxicity and apoptosis in human lung epithelial adenocarcinoma cells A549 and H1229. Antioxidants (Basel) 2020; 9: 357.

16.

Dai

Wang

Fan

, et al. Nrf2 transcriptional upregulation of IDH2 to tune mitochondrial dynamics and rescue angiogenic function of diabetic EPCs. Redox Biol 2022; 56: 102449.

17.

Gaike

Paul

Bhute

, et al. The gut microbial diversity of newly diagnosed diabetics but not of prediabetics is significantly different from that of healthy nondiabetics. mSystems 2020; 5: e00578–19.

18.

Chen

Huang

Liu

, et al. AMPK: a bridge between diabetes mellitus and Alzheimer's disease. Behav Brain Res 2021; 400: 113043.

19.

Zhang

Huang

Yan

, et al. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link. Behav Brain Res 2018; 339: 57–65.

20.

Huang

Jin

Zhou

, et al. TLR4 Is a link between diabetes and Alzheimer's disease. Behav Brain Res 2017; 316: 234–244.

21.

Sun

Dawuti

Gong

, et al. Puerarin-V improve mitochondrial respiration and cardiac function in a rat model of diabetic cardiomyopathy via inhibiting pyroptosis pathway through P2X7 receptors. Int J Mol Sci 2022; 23: 13015.

22.

Liu

Javaheri

Godar

, et al. Intermittent fasting preserves beta-cell mass in obesity-induced diabetes via the autophagy-lysosome pathway. Autophagy 2017; 13: 1952–1968.

23.

Chen

, et al. Icariside II exerts anti-type 2 diabetic effect by targeting PPARα/γ: involvement of ROS/NF-κB/IRS1 signaling pathway. Antioxidants (Basel) 2022; 11: 1705.

24.

Kim

Furuhashi

Takahashi

, et al. Late-afternoon endurance exercise is more effective than morning endurance exercise at improving 24-h glucose and blood lipid levels. Front Endocrinol (Lausanne) 2022; 13: 957239.

25.

Santamarina

Moraes

RCM

Nehmi Filho

, et al. The symbiotic effect of a new nutraceutical with yeast β-glucan, prebiotics, minerals, and Silybum marianum (silymarin) for recovering metabolic homeostasis via pgc-1α, il-6, and il-10 gene expression in a type-2 diabetes obesity model. Antioxidants (Basel) 2022; 11: 447.

26.

Robertson

. Nrf2 and antioxidant response in animal models of type 2 diabetes. Int J Mol Sci 2023; 24: 3082.

27.

Tumminia

Vinciguerra

Parisi

, et al. Type 2 diabetes mellitus and Alzheimer's disease: role of insulin signalling and therapeutic implications. Int J Mol Sci 2018; 19: 3306.

28.

Sędzikowska

Szablewski

. Insulin and insulin resistance in Alzheimer's disease. Int J Mol Sci 2021; 22: 9987.

29.

TKC

Dao

Nguyen

, et al. Insulin signaling and its application. Front Endocrinol (Lausanne) 2023; 14: 1226655.

30.

Saltiel

. Insulin signaling in health and disease. J Clin Invest 2021; 131: e142241.

31.

Park

Gautier

Chon

. Assessment of insulin secretion and insulin resistance in human. Diabetes Metab J 2021; 45: 641–654.

32.

Lee

Park

Choi

. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J 2022; 46: 15–37.

33.

Mirabelli

Chiefari

Arcidiacono

, et al. Mediterranean Diet nutrients to turn the tide against insulin resistance and related diseases. Nutrients 2020; 12: 1066.

34.

Russo

Menduni

Borboni

, et al. Autonomic nervous system in obesity and insulin-resistance-the complex interplay between leptin and central nervous system. Int J Mol Sci 2021; 22: 5187.

35.

Shpakov

Zorina

Derkach

. Hot spots for the use of intranasal insulin: cerebral ischemia, brain injury, diabetes mellitus, endocrine disorders and postoperative delirium. Int J Mol Sci 2023; 24: 3278.

36.

Bakker

Imbernon

Salinas

, et al. Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis. Cell Rep 2022; 41: 111698.

37.

Rhea

Banks

. Role of the blood-brain barrier in central nervous system insulin resistance. Front Neurosci 2019; 13: 521.

38.

Huang

van Zijl

PCM

Han

, et al. Altered d-glucose in brain parenchyma and cerebrospinal fluid of early Alzheimer's disease detected by dynamic glucose-enhanced MRI. Sci Adv 2020; 6: eaba3884.

39.

Anderson

Frazier

Maimaiti

, et al. Impact of single or repeated dose intranasal zinc-free insulin in young and aged F344 rats on cognition, signaling, and brain metabolism. J Gerontol A Biol Sci Med Sci 2017; 72: 189–197.

40.

Zaulkffali

Md Razip

Syed Alwi

, et al. Vitamins D and E stimulate the PI3K-AKT signalling pathway in insulin-resistant SK-N-SH neuronal cells. Nutrients 2019; 11: 2525.

41.

Gao

Hebbar

Gao

, et al. GSK-3β phosphorylation of cytoplasmic dynein reduces Ndel1 binding to intermediate chains and alters dynein motility. Traffic 2015; 16: 941–961.

42.

Arnold

Arvanitakis

Macauley-Rambach

, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol 2018; 14: 168–181.

43.

Aguayo-Mazzucato

van Haaren

Mruk

, et al. Β cell aging markers have heterogeneous distribution and are induced by insulin resistance. Cell Metab 2017; 25: 898–910. e895.

44.

Kellar

Craft

. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol 2020; 19: 758–766.

45.

Ruiz

Chi

Shin

, et al. Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer's disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels. Alzheimers Dement 2016; 12: 851–861.

46.

Clarke

Lyra

ESNM

Figueiredo

, et al. Alzheimer-associated aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med 2015; 7: 190–210.

47.

Scheltens

De Strooper

Kivipelto

, et al. Alzheimer's disease. Lancet 2021; 397: 1577–1590.

48.

Tiwari

Atluri

Kaushik

, et al. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomed 2019; 14: 5541–5554.

49.

Rad

Arya

Karimian

, et al. Mechanism involved in insulin resistance via accumulation of β-amyloid and neurofibrillary tangles: link between type 2 diabetes and Alzheimer's disease. Drug Des Devel Ther 2018; 12: 3999–4021.

50.

Gasparini

Gouras

Wang

, et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001; 21: 2561–2570.

51.

Park

Kang

Kim

, et al. Fucoidan-rich substances from Ecklonia cava improve trimethyltin-induced cognitive dysfunction via down-regulation of amyloid β production/tau hyperphosphorylation. Mar Drugs 2019; 17: 591.

52.

Mullins

Diehl

Chia

, et al. Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer's disease. Front Aging Neurosci 2017; 9: 118.

53.

Sousa

Guarda

Meneses

, et al. Insulin-degrading enzyme: an ally against metabolic and neurodegenerative diseases. J Pathol 2021; 255: 346–361.

54.

Yoon

Hwang

Son

, et al.

How can insulin resistance cause Alzheimer's disease?

Int J Mol Sci 2023; 24: 3506.

55.

Starks

Patrick

Grady

, , et al. Insulin resistance is associated with higher cerebrospinal fluid tau levels in asymptomatic APOEɛ4 carriers. J Alzheimers Dis 2015; 46: 525–533.

56.

Naseri

Wang

Guo

, et al. The complexity of tau in Alzheimer's disease. Neurosci Lett 2019; 705: 183–194.

57.

Cai

Liu

Wang

, et al. Microglia in the neuroinflammatory pathogenesis of Alzheimer's disease and related therapeutic targets. Front Immunol 2022; 13: 856376.

58.

Park

Jeon

, et al. Protective effect of genistein against neuronal degeneration in ApoE(-/-) mice fed a high-fat diet. Nutrients 2016; 8: 692.

59.

Burillo

Marqués

Jiménez

, et al. Insulin resistance and diabetes mellitus in Alzheimer's disease. Cells 2021; 10: 1236.

60.

Michailidis

Moraitou

Tata

, et al. Alzheimer's disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes. Int J Mol Sci 2022; 23: 2687.

61.

Freude

Hettich

Schumann

, et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J 2009; 23: 3315–3324.

62.

Killick

Scales

Leroy

, et al. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun 2009; 386: 257–262.

63.

Chen

, et al. D-ribose is elevated in T1DM patients and can be involved in the onset of encephalopathy. Aging 2019; 11: 4943–4969.

64.

Biundo

Del Prete

Zhang

, et al. A role for tau in learning, memory and synaptic plasticity. Sci Rep 2018; 8: 3184.

65.

Zhang

Hao

Manor

, et al. Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes. Diabetes 2015; 64: 1025–1034.

66.

Cree-Green

Scalzo

Harrall

, et al. Supplemental oxygen improves in vivo mitochondrial oxidative phosphorylation flux in sedentary obese adults with type 2 diabetes. Diabetes 2018; 67: 1369–1379.

67.

Ogura

Kitada

Monno

, et al. Renal mitochondrial oxidative stress is enhanced by the reduction of Sirt3 activity, in Zucker diabetic fatty rats. Redox Rep 2018; 23: 153–159.

68.

Barbiera

Sorrentino

Fard

, et al. Taurine administration counteracts aging-associated impingement of skeletal muscle regeneration by reducing inflammation and oxidative stress. Antioxidants (Basel) 2022; 11: 1016.

69.

Grases

Colom

Fernandez

, et al. Evidence of higher oxidative status in depression and anxiety. Oxid Med Cell Longev 2014; 2014: 430216.

70.

Mazzoli

Spagnuolo

Gatto

, et al.

Adipose tissue and brain metabolic responses to Western diet-is there a similarity between the two?

Int J Mol Sci 2020; 21: 786.

71.

Ruegsegger

Vanderboom

Dasari

, et al. Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain. JCI Insight 2019; 4: e130681.

72.

Kornelius

Lin

Chang

, et al. DPP-4 inhibitor linagliptin attenuates Aβ-induced cytotoxicity through activation of AMPK in neuronal cells. CNS Neurosci Ther 2015; 21: 549–557.

73.

Chen

Chiang

Lin

, et al. Lysophosphatidic acid receptor LPA(3) prevents oxidative stress and cellular senescence in Hutchinson-Gilford progeria syndrome. Aging Cell 2020; 19: e13064.

74.

Kyozuka

Murata

Isogami

, et al. Preconception dietary inflammatory index and risk of gestational diabetes mellitus based on maternal body mass index: findings from a Japanese birth cohort study. Nutrients 2022; 14: 4100.

75.

Touyz

Rios

Alves-Lopes

, et al. Oxidative stress: a unifying paradigm in hypertension. Can J Cardiol 2020; 36: 659–670.

76.

Liang

Hao

Yao

, et al. Hypericin maintians PDX1 expression via the Erk pathway and protects islet β-cells against glucotoxicity and lipotoxicity. Int J Biol Sci 2019; 15: 1472–1487.

77.

Byrne

Rajasekaran

Abel

, et al. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. Free Radic Biol Med 2021; 169: 317–342.

78.

Das

Sahu

, et al. Identification and characterization of circular intronic RNAs derived from insulin gene. Int J Mol Sci 2020; 21: 4302.

79.

Zhou

Sun

Chen

, et al. Phenylalanine impairs insulin signaling and inhibits glucose uptake through modification of IRβ. Nat Commun 2022; 13: 4291.

80.

Ferira

Laing

Hausman

, et al. Vitamin D supplementation does not impact insulin resistance in black and white children. J Clin Endocrinol Metab 2016; 101: 1710–1718.

81.

Bellan

Guzzaloni

Rinaldi

, et al. Altered glucose metabolism rather than naive type 2 diabetes mellitus (T2DM) is related to vitamin D status in severe obesity. Cardiovasc Diabetol 2014; 13: 57.

82.

Tiwari

Pandey

Abidi

, et al. Markers of oxidative stress during diabetes mellitus. J Biomark 2013; 2013: 378790.

83.

Choi

, et al. Oxidative stress and calcium dysregulation by palmitate in type 2 diabetes. Exp Mol Med 2017; 49: e291.

84.

Marrano

Biondi

Borrelli

, et al. Type 2 diabetes and Alzheimer's disease: the emerging role of cellular lipotoxicity. Biomolecules 2023; 13: 183.

85.

Birla

Minocha

Kumar

, et al. Role of oxidative stress and metal toxicity in the progression of Alzheimer's disease. Curr Neuropharmacol 2020; 18: 552–562.

86.

Nikooyeh

Neyestani

. Oxidative stress, type 2 diabetes and vitamin D: past, present and future. Diabetes Metab Res Rev 2016; 32: 260–267.

87.

Ahmad

Ijaz

Shabbiri

, et al. Oxidative toxicity in diabetes and Alzheimer's disease: mechanisms behind ROS/ RNS generation. J Biomed Sci 2017; 24: 76.

88.

Tsai

Chang

Lai

, et al. Pomalidomide ameliorates H₂O₂-induced oxidative stress injury and cell death in rat primary cortical neuronal cultures by inducing anti-oxidative and anti-apoptosis effects. Int J Mol Sci 2018; 19: 3252.

89.

Zhu

Wang

, et al. Acrolein, an endogenous aldehyde induces synaptic dysfunction in vitro and in vivo: involvement of RhoA/ROCK2 pathway. Aging Cell 2022; 21: e13587.

90.

Scheff

Ansari

Mufson

. Oxidative stress and hippocampal synaptic protein levels in elderly cognitively intact individuals with Alzheimer's disease pathology. Neurobiol Aging 2016; 42: 1–12.

91.

Rickards

Lynn

Harrop

, et al. Effect of polyphenol-rich foods, juices, and concentrates on recovery from exercise induced muscle damage: a systematic review and meta-analysis. Nutrients 2021; 13: 2988.

92.

González-Burgos

Ureña-Vacas

Sánchez

, et al. Nutritional value of moringa oleifera lam. Leaf powder extracts and their neuroprotective effects via antioxidative and mitochondrial regulation. Nutrients 2021; 13: 2203.

93.

Pasha

Chua

JJE

. Redox changes and cellular senescence in Alzheimer's disease. Redox Biol 2024; 70: 103048.

94.

Boyd-Kimball

Sultana

Poon

, et al. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1–42) into rat brain: implications for Alzheimer's disease. Neuroscience 2005; 132: 313–324.

95.

Arimon

Takeda

Post

, et al. Oxidative stress and lipid peroxidation are upstream of amyloid pathology. Neurobiol Dis 2015; 84: 109–119.

96.

Butterfield

Boyd-Kimball

. Oxidative stress, amyloid-β peptide, and altered key molecular pathways in the pathogenesis and progression of Alzheimer's disease. J Alzheimers Dis 2018; 62: 1345–1367.

97.

Abdallah

El Sayed

Sirwi

, et al. Mangostanaxanthone IV ameliorates streptozotocin-induced neuro-inflammation, amyloid deposition, and tau hyperphosphorylation via modulating PI3K/Akt/GSK-3β pathway. Biology 2021; 10: 1298.

98.

Wang

. The neuroprotective and neurodegeneration effects of heme oxygenase-1 in Alzheimer's disease. J Alzheimers Dis 2020; 78: 1259–1272.

99.

Liu

Yang

, et al. Heme oxygenase-1: the roles of both good and evil in neurodegenerative diseases. J Neurochem 2023; 167: 347–361.

100.

Veselov

Vinogradova

Maltsev

, et al. Mitochondria and oxidative stress as a link between Alzheimer's disease and diabetes mellitus. Int J Mol Sci 2023; 24: 14450.

101.

Eleutherio

ECA

Silva Magalhães

de Araújo Brasil

, et al. SOD1, More than just an antioxidant. Arch Biochem Biophys 2021; 697: 108701.

102.

Trist

Hilton

Hare

, et al. Superoxide dismutase 1 in health and disease: how a frontline antioxidant becomes neurotoxic. Angew Chem Int Ed Engl 2021; 60: 9215–9246.

103.

Youssef

Chami

Lim

, et al. Evidence supporting oxidative stress in a moderately affected area of the brain in Alzheimer's disease. Sci Rep 2018; 8: 11553.

104.

Yang

Sheng

Guo

, et al. Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer's disease. Biomaterials 2020; 238: 119844.

105.

Grimm

Regner

Mett

, et al. Tocotrienol affects oxidative stress, cholesterol homeostasis and the amyloidogenic pathway in neuroblastoma cells: consequences for Alzheimer's disease. Int J Mol Sci 2016; 17: 1809.

106.

Lanzillotta

Di Domenico

Perluigi

, et al. Targeting mitochondria in Alzheimer disease: rationale and perspectives. CNS Drugs 2019; 33: 957–969.

107.

Jia

Zhang

Sun

, et al. Impact of the glycemic level on the salivary proteome of middle-aged and elderly people with type 2 diabetes mellitus: an observational study. Front Mol Biosci 2021; 8: 790091.

108.

Byon

Han

, et al. Txnip ablation reduces vascular smooth muscle cell inflammation and ameliorates atherosclerosis in apolipoprotein E knockout mice. Atherosclerosis 2015; 241: 313–321.

109.

Réus

Dos Santos

Abelaira

, et al. Antioxidant treatment ameliorates experimental diabetes-induced depressive-like behaviour and reduces oxidative stress in brain and pancreas. Diabetes Metab Res Rev 2016; 32: 278–288.

110.

Habibe

Clemente-Olivo

Scheithauer

TPM

, et al. Glucose-mediated insulin secretion is improved in FHL2-deficient mice and elevated FHL2 expression in humans is associated with type 2 diabetes. Diabetologia 2022; 65: 1721–1733.

111.

Xiafukaiti

Maimaiti

Ogata

, et al. Mafb is important for pancreatic β-cell maintenance under a MafA-deficient condition. Mol Cell Biol 2019; 39: e00080–19.

112.

El Khattabi

Sharma

. Preventing p38 MAPK-mediated MafA degradation ameliorates β-cell dysfunction under oxidative stress. Mol Endocrinol 2013; 27: 1078–1090.

113.

Yang

Liu

, et al. Methylmercury induces mitochondria- and endoplasmic reticulum stress-dependent pancreatic β-cell apoptosis via an oxidative stress-mediated JNK signaling pathway. Int J Mol Sci 2022; 23: 2858.

114.

Zhang

, et al. Oxidative stress: a common pathological state in a high-risk population for osteoporosis. Biomed Pharmacother 2023; 163: 114834.

115.

Malko

Ding

Jiang

. TRPM2 Channel in oxidative stress-induced mitochondrial dysfunction and apoptotic cell death. Adv Protein Chem Struct Biol 2021; 125: 51–72.

116.

Ghzaiel

Zarrouk

Nury

, et al. Antioxidant properties and cytoprotective effect of Pistacia lentiscus L. seed oil against 7β-hydroxycholesterol-induced toxicity in C2C12 myoblasts: reduction in oxidative stress, mitochondrial and peroxisomal dysfunctions and attenuation of cell death. Antioxidants (Basel, Switzerland) 2021; 10: 1772.

117.

Suren Garg

Kushwaha

Dubey

, et al. Association between obesity, inflammation and insulin resistance: insights into signaling pathways and therapeutic interventions. Diabetes Res Clin Pract 2023; 200: 110691.

118.

Khalid

Alkaabi

Khan

MAB

, et al. Insulin signal transduction perturbations in insulin resistance. Int J Mol Sci 2021; 22: 8590.

119.

Inoue-Yanagimachi

Himori

Uchida

, et al. Changes in glial cells and neurotrophic factors due to rotenone-induced oxidative stress in Nrf2 knockout mice. Exp Eye Res 2023; 226: 109314.

120.

Cheung

Lee

Khor

, et al. Nrf2 knockout enhances intestinal tumorigenesis in Apc(min/+) mice due to attenuation of anti-oxidative stress pathway while potentiates inflammation. Mol Carcinog 2014; 53: 77–84.

121.

Huang

Cui

, et al. Clinical antidiabetic medication used in Alzheimer's disease: from basic discovery to therapeutics development. Front Aging Neurosci 2023; 15: 1122300.

122.

Markowicz-Piasecka

Sikora

Szydłowska

, et al. Metformin – A future therapy for neurodegenerative diseases: theme: drug discovery, development and delivery in Alzheimer's disease guest editor: davide brambilla. Pharm Res 2017; 34: 2614–2627.

123.

Zhu

Wang

Wallack

, et al. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. Mol Psychiatry 2015; 20: 252–262.

124.

Grizzanti

Corrigan

Casadesus

. Neuroprotective effects of amylin analogues on Alzheimer's disease pathogenesis and cognition. J Alzheimers Dis 2018; 66: 11–23.

125.

Jain

Sarsaiya

Gong

, et al. Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii tratt: a comprehensive review. Pharmacol Ther 2024; 259: 108657.

126.

Pramanik

Dey

Chakrabarty

, et al. Diabetes mellitus and Alzheimer's disease: understanding disease mechanisms, their correlation, and promising dual activity of selected herbs. J Ethnopharmacol 2024; 333: 118402.

127.

Cheng

. Study on the effect and mechanisms of Dendrobium nobile Lindl. Alkaloids on blood glucose in KK-Ay mice. Zunyi: Zunyi Medical University, 2019.

128.

Zhang

. The Effect of Dendrobium nobile Lindl. Alkaloids on Blood Glucose in db/db Mice and the Mechanisms. Zunyi: Zunyi Medical University, 2016.

129.

Liu

. The Effect of Dendrobium nobile Lindl. Alkaloids on liver Fat Metabolism in Hypercholesterolemia Model Mice. Zunyi: Zunyi Medical University, 2020.

130.

Zhang

, et al. Protective effects of dendrobium nobile lindl. alkaloids on amyloid beta (25–35)-induced neuronal injury. Neural Regen Res 2017; 12: 1131–1136.

131.

Zhang

, et al. Dendrobium nobile lindl. alkaloids ameliorate Aβ25–35-induced synaptic deficits by targeting wnt/β-catenin pathway in Alzheimer's disease models. J Alzheimers Dis 2022; 86: 297–313.

132.

Lang

Liu

, et al. Protective effects of Dendrobium nobile lindl. alkaloids on Alzheimer's disease-like symptoms induced by high-methionine diet. Curr Neuropharmacol 2022; 20: 983–997.

133.

Liu

Huang

Liu

, et al. Dendrobium nobile lindl alkaloid and metformin ameliorate cognitive dysfunction in senescence-accelerated mice via suppression of endoplasmic reticulum stress. Brain Res 2020; 1741: 146871.

134.

Liu

, et al. Dendrobium nobile lindl. alkaloids ameliorate cognitive dysfunction in senescence accelerated SAMP8 mice by decreasing amyloid-β aggregation and enhancing autophagy activity. J Alzheimers Dis 2020; 76: 657–669.

135.

Nie

Jiang

Zhang

, et al. Dendrobium nobile lindl. alkaloids decreases the level of intracellular β-amyloid by improving impaired autolysosomal proteolysis in APP/PS1 mice. Front Pharmacol 2018; 9: 1479.

136.

. Alkaloids of Dendrobium nobile Lindl attenuate cell damage induced by Aβ via activating autophagy . Doctor Degree, Shanghai Jiao Tong University School of Medicine, 2019.

137.

Liu

Yang

, et al. Protective effects and mechanisms of Dendrobium nobile lindl. alkaloids on PC12 cell damage induced by Aβ (25–35). Behav Neurol 2021; 2021: 9990375.